Business Context and Reporting Period
This Form 8-K Current Report was filed by Miragen Therapeutics, Inc. (Note: The request metadata listed "Viridian Therapeutics," but the filing text identifies the registrant as Miragen Therapeutics) on December 11, 2019. The report details a material definitive agreement for equity financing, the termination of a patent license, a restructuring plan involving workforce reductions, and significant updates to the company's clinical pipeline and executive leadership.
Key Financial Metrics and Liquidity
- Financing Agreement: Entered into a Common Stock Purchase Agreement with Aspire Capital Fund, LLC for up to $20.0 million over 30 months.
- Initial Proceeds: Received $1.0 million immediately upon execution for the sale of 1,598,465 shares at $0.6256 per share.
- Commitment Shares: Issued 959,079 shares to Aspire Capital as consideration for entering the agreement.
- Restructuring Costs: Estimated $0.7 million in charges for the current reduction of approximately 18 employees, with total 2019 restructuring charges reaching approximately $1.1 million and an additional $1.0 million anticipated through June 30, 2020.
- Liquidity Outlook: Management believes cash and cash equivalents are sufficient to fund operations into the fourth quarter of 2020.
- Revenue: The company currently generates no revenue from product sales.
Material Changes vs. Prior Period
- Capital Structure: Significant dilution potential via the new $20.0 million facility with Aspire Capital, capped at approximately 19.99% of outstanding shares without further shareholder approval.
- Operational Restructuring: Announcement of a plan to reduce the workforce by approximately 18 employees, primarily in R&D and support functions, to streamline operations.
- Contract Termination: Terminated the Exclusive Patent License Agreement with The Brigham and Women's Hospital (BWH), effective March 8, 2020, ending rights to specific microRNA patent rights related to neurodegenerative disorders.
- Leadership Changes: Paul Rubin, M.D., Executive Vice President of R&D, is departing effective December 31, 2019. Diana Escolar, M.D., was promoted to Chief Medical Officer.
Guidance, Outlook, and Risks
Clinical Pipeline Updates
- Cobomarsen (miR-155 inhibitor): Enrollment in the Phase 2 SOLAR trial for cutaneous T-cell lymphoma (CTCL) was stopped, reducing the target from 126 to approximately 30 patients. The company is now focusing expansion efforts on Adult T-cell Leukemia/Lymphoma (ATLL) and plans an FDA meeting in Q2 2020 to explore an expedited pathway. Topline CTCL data is expected in Q3 2020.
- Remlarsen (miR-29 mimic): Interim Phase 2 data for keloid scars showed safety and initial volume reductions. The company will continue analysis to the one-year endpoint and seeks a collaboration partner.
- MRG-229 (miR-29 mimic): Future capital allocation will primarily focus on MRG-229 for Idiopathic Pulmonary Fibrosis (IPF). Preclinical data is expected in the first half of 2020.
- MRG-110: Rights to this candidate were regained following the termination of the Servier Collaboration Agreement. Future development depends on capital availability.
Risks and Contingencies
- Capital Constraints: The company may need to finance sooner than anticipated if it cannot meet milestones under its Leukemia and Lymphoma Society (LLS) Stock Purchase Agreement, potentially forfeiting $3.5 million in remaining proceeds.
- Dilution: Sales under the Aspire Capital agreement and existing ATM agreements may cause substantial dilution and downward pressure on the stock price.
- Development Uncertainty: No product candidates have received regulatory approval. The company faces risks regarding patient enrollment, clinical trial outcomes, and the ability to secure future funding.
Investor Verification Checklist
- Verify the exact number of shares issued under the Aspire Capital agreement and the remaining capacity under the $20.0 million facility.
- Confirm the timeline and specific outcomes of the FDA meeting regarding cobomarsen in ATLL scheduled for Q2 2020.
- Monitor the finalization of the $0.7 million restructuring charge and the impact on the Q4 2020 cash runway.
- Review the status of the LLS Stock Purchase Agreement to determine if the $3.5 million in potential proceeds will be realized or if alternative financing is required.
- Assess the implications of the BWH license termination on the company's intellectual property portfolio regarding neurodegenerative disorders.